Literature DB >> 1249209

A role for alpha-adrenergic receptors in abnormal insulin secretion in diabetes mellitus.

R P Robertson, J B Halter, D Porte.   

Abstract

To determine whether endogenous alpha-adrenergic activity contributes to abnormal insulin secretion in nonketotic, hyperglycemic, diabetic patients, alpha-adrenergic blockade was produced in normal and diabetic subjects. The diabetics had a significantly (P less than 0.01) greater increase in circulating insulin 1 h after an intravenous phentolamine infusion than did the normal subjects. During the phentolamine infusion, there was also a significant augmentation of acute insulin responses to intravenous glucose (20 g) pulses in normal subjects (P less than 0.05) and diabetics (P less than 0.02); this augmentation was fivefold greater in the diabetics. Simultaneous treatment with the beta-adrenergic blocking agent, propranolol, did not alter these findings. Thus a role for exaggerated endogenous alpha-adrenergic activity in abnormal insulin secretion of the diabetic subjects is suggested. To determine whether this alpha-adrenergic activity might be related to elevated circulating catecholamines, total plasma-catecholamine levels were compared in normal and nonketotic diabetic subjects given intravenous glucose pulses. These levels were significantly greater (P less than 0.02) in the diabetic compared to the normal group before the glucose pulse, and increased significantly in both groups (P less than 0.02 and less than 0.001, respectively) after the pulse. These data suggest that excessive catecholamine secretion may lead to an abnormal degree of endogenous alpha-adrenergic activity, which contributes to defective insulin secretion in diabetic subjects.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1249209      PMCID: PMC436715          DOI: 10.1172/JCI108338

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  11 in total

1.  Plasma catecholamine responses to intravenous glucose in normal man.

Authors:  R P Robertson; D Porte
Journal:  J Clin Endocrinol Metab       Date:  1974-08       Impact factor: 5.958

2.  Paradoxical hypoinsulinaemia: an alpha-adrenergic-mediated response to glucose.

Authors:  R P Robertson; J D Brunzell; W R Hazzard; R L Lerner; D Porte
Journal:  Lancet       Date:  1972-10-14       Impact factor: 79.321

3.  Plasma noradrenaline and adrenaline in patients with thyrotoxicosis and myxoedema.

Authors:  N J Christensen
Journal:  Clin Sci Mol Med       Date:  1973-08

4.  Relationship between intravenous glucose loads, insulin responses and glucose disappearance rate.

Authors:  R L Lerner; D Porte
Journal:  J Clin Endocrinol Metab       Date:  1971-09       Impact factor: 5.958

5.  Adrenergic modulation of basal insulin secretion in man.

Authors:  R P Robertson; D Porte
Journal:  Diabetes       Date:  1973-01       Impact factor: 9.461

6.  A sensitive and specific double-isotope derivative method for the determination of catecholamines in biological specimens.

Authors:  K Engelman; B Portnoy; W Lovenberg
Journal:  Am J Med Sci       Date:  1968-04       Impact factor: 2.378

7.  Plasma norepinephrine and epinephrine in untreated diabetics, during fasting and after insulin administration.

Authors:  N J Christensen
Journal:  Diabetes       Date:  1974-01       Impact factor: 9.461

8.  A receptor mechanism for the inhibition of insulin release by epinephrine in man.

Authors:  D Porte
Journal:  J Clin Invest       Date:  1967-01       Impact factor: 14.808

9.  Increase of insulin concentration in maturity-onset diabetics by phentolamine (Regitine) infusion.

Authors:  J Linde; T Deckert
Journal:  Horm Metab Res       Date:  1973-11       Impact factor: 2.936

10.  The glucose receptor. A defective mechanism in diabetes mellitus distinct from the beta adrenergic receptor.

Authors:  R P Robertson; D Porte
Journal:  J Clin Invest       Date:  1973-04       Impact factor: 14.808

View more
  37 in total

Review 1.  Drug treatment of non-insulin-dependent diabetes mellitus in the 1990s. Achievements and future developments.

Authors:  A J Scheen
Journal:  Drugs       Date:  1997-09       Impact factor: 9.546

2.  Imidazoline antagonists of alpha 2-adrenoceptors increase insulin release in vitro by inhibiting ATP-sensitive K+ channels in pancreatic beta-cells.

Authors:  J C Jonas; T D Plant; J C Henquin
Journal:  Br J Pharmacol       Date:  1992-09       Impact factor: 8.739

3.  A preliminary, clinical pharmacological assessment of L-659,066, a novel alpha 2-adrenoceptor antagonist.

Authors:  R F Schafers; H L Elliott; C A Howie; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1992-12       Impact factor: 4.335

4.  Preservation of insulin mRNA levels and insulin secretion in HIT cells by avoidance of chronic exposure to high glucose concentrations.

Authors:  R P Robertson; H J Zhang; K L Pyzdrowski; T F Walseth
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

Review 5.  The beta cell lesion in type 2 diabetes: there has to be a primary functional abnormality.

Authors:  S E Kahn; S Zraika; K M Utzschneider; R L Hull
Journal:  Diabetologia       Date:  2009-03-27       Impact factor: 10.122

6.  Towards a genotype-based approach for a patient-centered pharmacologic therapy of type 2 diabetes.

Authors:  André J Scheen
Journal:  Ann Transl Med       Date:  2015-05

Review 7.  Pathogenesis of impaired glucose tolerance and type II diabetes mellitus--current status.

Authors:  M B Davidson
Journal:  West J Med       Date:  1985-02

8.  Duration of residual B-cell function in maturity-onset diabetes.

Authors:  M Cignarelli; M R Cospite; G Stefanelli; E Guastamacchia; G Nardelli; R Giorgino
Journal:  Acta Diabetol Lat       Date:  1984 Apr-Jun

9.  Identification of an alpha-adrenoceptor binding inhibitor: possible implications in diabetes mellitus.

Authors:  M D Wider; J C Dunbar; P M Duhaime
Journal:  Acta Diabetol Lat       Date:  1985 Jul-Sep

10.  Biochemical, Physiological and Psychological Changes During Endurance Exercise in People With Type 1 Diabetes.

Authors:  Neil E Hill; Christopher Campbell; Paul Buchanan; Midge Knight; Ian F Godsland; Nick S Oliver
Journal:  J Diabetes Sci Technol       Date:  2016-09-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.